Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Almased USA, Inc.
WARNING LETTER
•Almased USA, Inc.•January 31, 2012

Almased USA, Inc. – FDA Warning Letter, Jan 31, 2012

Record Details

On January 18, 2012, the FDA issued a Warning Letter to Almased USA, Inc. after reviewing their website (www.almased.com) and "The Weight Loss Program" booklet in January 2012. The FDA determined that the "Almased?" product, labeled as a dietary supplement, was promoted for conditions that classify it as a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act).

The therapeutic claims on the website and in the booklet establish the product as a drug intended for the cure, mitigation, treatment, or prevention of disease, violating the Act. Examples of claims include "beneficial effects of Almased? on ... obese individuals," "Almased? can be extremely helpful for people with diabetes," "significantly lowers insulin level as well as the HbA1c level," "reduce blood pressure and cholesterol levels," and "actively fights ... high blood pressure and insulin resistance." Testimonials also claimed the product helped normalize glucose, cholesterol, and triglycerides, and allowed a user to stop diabetes medication. Metatags like "blood sugar level control" further supported these claims.

The FDA stated that Almased? is a "new drug" under section 201(p) of the Act because it is not generally recognized as safe and effective for these uses and lacks prior FDA approval. Furthermore, the product is mis

Company
Almased USA, Inc.
Inspection date
January 31, 2012
Product type
Drugs
Office
Florida District Office
Person
  • Emma R. Singleton (District Director)
View Company Profile

ID · 38525569-8eba-4d17-8e59-643054340e39

Violation Codes5
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(p)21.U.S.C. 355(a)21 U.S.C. 352(t)(1)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Almased USA, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.